孟鲁司特钠联合丙酸倍氯米松雾化吸入对 CVA患儿的影响

Effect of atomized Inhalation of Montelukast Sodium combined with Beclomethasone Propionate on Children with CVA

目的探讨孟鲁司特钠联合丙酸倍氯米松雾化吸入治疗对咳嗽变异性哮喘(CVA)患儿的影响。方法选取2020年1月至2021年8月在光山县人民医院确诊的116例CVA患儿,采用随机分组将患儿分为观察组(采用孟鲁司特钠联合丙酸倍氯米松雾化吸入治疗)和对照组(采用丙酸倍氯米松雾化吸入治疗),各58例。治疗均持续3个月。评估治疗后的临床疗效,治疗前后咳嗽症状、肺功能及血清炎症因子水平。记录两组不良反应和治疗6个月后复发情况。结果观察组治疗有效率高于对照组,差异有统计学意义(P<0.05);治疗后,观察组日间、夜间咳嗽积分、第1秒用力呼气的肺容积(FEV1)、用力肺活量(FVC)及第1秒用力呼气肺活量与用力肺活量之比(FEV1/FVC)高于对照组,差异有统计学意义(P<0.05);IL-4、IL-1β、IL-8水平及复发率低于对照组,差异有统计学意义(P<0.05)。观察组与对照组的不良反应发生率,差异无统计学意义(P>0.05)。结论孟鲁司特钠联合丙酸倍氯米松雾化吸入治疗可以明显提高CVA患儿的临床疗效,快速改善患儿临床症状及肺功能,降低复发率。

Objective To investigate the effect of aerosol inhalation of montelukast sodium combined with beclomethasone propionate on children with cough variant asthma(CVA).Methods A total of 116 children with CVA diagnosed in Guangshan County People's Hospital from January 2020 to August 2021 were randomly divided into an observation group(treated with aerosol inhalation of montelukast sodium combined with beclomethasone propionate)and a control group(treated with aerosol inhalation of beclomethasone propionate),with 58 cases in each group.The treatment lasted for 3 months.The clinical efficacy,cough symptoms,lung function,and serum inflammatory factor levels before and after treatment were evaluated,the adverse reactions and recurrence after 6 months of treatment in both groups were record.Results The effective rate of treatment in the observation group was higher than that in the control group,with a statistically significant difference(P<0.05);After treatment,the daytime and nighttime cough scores,forced expiratory lung volume in the first second(FEV1),forced vital capacity(FVC),and the ratio of forced expiratory vital capacity to forced vital capacity in the first second(FEV1/FVC)in the observation group were significantly higher than those in the control group,the difference was statistically significant(P<0.05);The levels of IL-4,IL-1β,IL-8 and recurrence rate were lower than those of the control group,with statistically significant differences(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the observation group and the control group(P>0.05).Conclusions The atomized inhalation of montelukast sodium combined with beclomethasone propionate can significantly improve the clinical efficacy of children with CVA,rapidly improve the clinical symptoms and pulmonary function of children,and reduce the recurrence rate.